The drug discount program is under scrutiny on a variety of fronts ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more ...

Washingtonians are struggling to afford already high health care costs, and those costs keep climbing. Sadly, I’ve seen this ...

The hospital lobby is asking federal officials to head off expanded data collection policies some drugmakers are implementing for providers participating in the 340B drug discount program.

A new report paints a stark picture of how a subset of large healthcare providers are drawing the lion’s share of 340B savings within a single state.  | A Minnesota analysis of providers' reported ...

A new Ohio bill won't expand the 340B program, but it will protect patients' ability to fill prescriptions at their pharmacy of choice.

The 340B program requires pharmaceutical manufacturers to sell drugs at significant discounts — in some cases, extremely steep discounts — to hospitals and clinics serving large numbers of uninsured ...

The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on ...

AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.

Hospitals and contract pharmacies are not required to pass those savings directly to patients at the pharmacy counter. | ...

AHA urges HHS to block Novo Nordisk's 340B data demand, citing legal and cost concerns for safety-net hospitals and covered entities.

AbbVie loses bid to block Tennessee 340B law as federal court upholds state statute limiting drugmaker restrictions on contract pharmacies.